MedTrace Logo

COVID-19 Vaccination Detoxification in LDL-C

NCT05839236 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-05-06

No results posted yet for this study

Summary

The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host in Low Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from the intervention trial with NCT number NCT05711810. It tests the use of Atorvastatin Calcium Tablets for detoxification and prevention of blood acidification, and the use of the Chinese herb compounded Anti-Viral Granules for the detoxification in the endocrine system.

Conditions

  • COVID-19 Stress Syndrome
  • COVID-19 Vaccine Adverse Reaction
  • COVID-19-Associated Thromboembolism
  • COVID-19 Post-Intensive Care Syndrome
  • COVID-19-Associated Stroke
  • COVID-19 Respiratory Infection

Interventions

COMBINATION_PRODUCT

Atorvastatin Calcium Tablets

The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.

Sponsors & Collaborators

  • Yang I. Pachankis

    lead INDIV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2023-06-30
Completion
2023-07-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05839236 on ClinicalTrials.gov